"2013 was a transformational year for CTI, as we entered into a worldwide license agreement with Baxter International to develop and commercialize our JAK2/FLT3 inhibitor, pacritinib, achieved favorable reimbursement and market access for PIXUVRI in major European markets and reported new positive interim data for tosedostat," stated James A. Bianco, M.D., President and CEO."